| Literature DB >> 32069879 |
Charles J Russell1,2, Rhiannon R Penkert1, Sonnie Kim3, Julia L Hurwitz1,2.
Abstract
Human metapneumovirus (HMPV) infects most children by five years of age. The virus can cause both upper and lower respiratory tract disease and can be life threatening. High-risk populations include young children who are exposed to virus for the first time and the elderly. Currently, there is no standard treatment nor licensed vaccine for HMPV, although several attractive vaccine candidates have been developed for pre-clinical studies. A raised awareness of the impact of HMPV on public health is needed to drive research, complete vaccine development, and thereby prevent significant virus-associated morbidities and mortalities worldwide.Entities:
Keywords: Sendai virus; respiratory virus infection; vaccine development
Year: 2020 PMID: 32069879 DOI: 10.3390/pathogens9020109
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817